EP Patent

EP4324477A3 — Oxabicycloheptanes for modulation of immune response

Assigned to Lixte Biotechnology Inc · Expires 2024-05-22 · 2y expired

What this patent protects

The present invention provides a method of treating a subject afflicted with cancer comprising administering to the subject an effective amount of a PP2A inhibitor.

USPTO Abstract

The present invention provides a method of treating a subject afflicted with cancer comprising administering to the subject an effective amount of a PP2A inhibitor.

Drugs covered by this patent

Zolinza (VORINOSTAT) · Merck & Co.

Patent Metadata

Patent number: EP4324477A3
Jurisdiction: EP
Classification: —
Expires: 2024-05-22
Drug substance claim: No
Drug product claim: No
Assignee: Lixte Biotechnology Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.